The information contained in this area of the website is for the purposes of AIM Rule 26.

Business Description:

About Diaceutics: 

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global lab network and product suite tailored for precision testing.

A full description of the business can be found here - Company Profile

To learn more about the Company, please watch the video of our recent 2023 Investor Roadshow

Board of Directors

The names of the directors and biographical details can be found here - Board of Directors

Corporate Governance

Information on Corporate Governance can be found here - Corporate Governance

UK Takeover Code Applicability

The Company is subject to the provisions of the UK City Code on Takeover and Mergers.

Country of Incorporation & Operations

The Company was incorporated and registered in Northern Ireland with registered number NI055207. Its main country of operation is Northern Ireland with wholly owned subsidiary undertakings in Northern Ireland, the Republic of Ireland, the US and Singapore.

Registered Office and principal trading address

First Floor
Building Two
Dataworks at Kings Hall Health & Wellbeing Park
Belfast
County­ Antrim
BT9 6GW

Current Constitutional Documents

The Articles of Association are available to download here.
The Admission document is available to download here.

Details of Restrictions on the transfer of Securities

There are no restrictions on the transfer of the Company’s ordinary shares.

Statement of the Rights of Shareholders

The rights of shareholders are governed by UK law.

Details of any other exchanges or trading platform

The securities of the Company are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.

Securities Information

 AIM securities in issue: 84,712,668

The percentage of AIM securities not in public hands at 24 May 2024 was 35.12%.

The identity and shareholdings of the Company's significant shareholders can be found here - Significant Shareholders

 

The documents sent to shareholders can be found here.

2021
2022
2023
Notice of Annual General Meeting 2021
Notice of Annual General Meeting 2022
Notice of Annual General Meeting 2023
Form of Proxy for Annual General Meeting 2021
Form of Proxy for Annual General Meeting 2022
Form of Proxy for Annual General Meeting 2023






Adviser Information

To view the details of the Company’s Advisers please click here

Regulatory News

To access notifications made by the Company please click here

Information Update

This information was last updated on 24 May 2024.